J. Kolesar

J. Kolesar, L. Vermeulen, E. Mancl, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

J. Kolesar, Lauren McGinty, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems

Allen J. Flynn, M. Crismon, J. Kolesar, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of an oral simulated FOLFOX with high dose capecitabine

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Investigational New Drugs.

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer

J. Berlin, J. Kolesar, James P. Thomas, 2002, International journal of gastrointestinal cancer.

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

K. Anderson, P. Richardson, J. Kolesar, 2012, Expert opinion on drug metabolism & toxicology.

Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.

J. Kolesar, A. Rounds, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

G. Wilding, J. Kolesar, J. Eickhoff, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Treatment of chronic myelogenous leukemia.

J. Kolesar, Christine Kujak, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

G. Wilding, J. Kolesar, K. Wisinski, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography

R. Jeraj, J. Kolesar, S. Perlman, 2015, Cancer Chemotherapy and Pharmacology.

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

C. Shapiro, J. Kolesar, M. Villalona-Calero, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

J. Kolesar, J. Schiller, M. Mazurczak, 2010, Investigational New Drugs.

Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells.

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2011, Oncology letters.

Pharmacogenomic potential in advanced cancer patients

J. Kolesar, H. Weiss, S. Arnold, 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

H. Parnes, J. Kolesar, KyungMann Kim, 2019, Cancer Prevention Research.

Exemestane for primary prevention of breast cancer in postmenopausal women.

J. Kolesar, Yang Zhang, K. Simondsen, 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Bevacizumab: improved survival at what cost?

J. Kolesar, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Direct quantification of AD-36 adenovirus DNA by capillary electrophoresis with laser-induced fluorescence.

J. Kolesar, N. Dhurandhar, J. Miller, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

J. Kolesar, KyungMann Kim, T. Campbell, 2014, Investigational New Drugs.

New treatment options for castration-resistant prostate cancer.

J. Kolesar, K. Simondsen, Katherine Simondsen, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Defective DNA repair in hereditary ovarian cancers: Implications for therapy

J. Kolesar, B. Burgess, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Warfarin—5‐FU Interaction — A Consecutive Case Series

J. Berlin, J. Kolesar, J. Schiller, 1999, Pharmacotherapy.

Quantification of ï ¡-Tocopherol in Smokers and Non-Smokers Before and After Supplementation: Mechanism of Failure for Vitamin E in Prostate Cancer Prevention?

J. Kolesar, 2017 .

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer

E. Messing, H. Parnes, J. Kolesar, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer.

J. Kolesar, H. Burris, J. Kuhn, 1995, Journal of the National Cancer Institute.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

H. Parnes, J. Kolesar, KyungMann Kim, 2017, Cancer Prevention Research.

Biliary tract large cell neuroendocrine carcinoma: current evidence

J. Kolesar, B. Evers, S. Arnold, 2019, Orphanet Journal of Rare Diseases.

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.

J. Kolesar, Igor N Ivashko, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

C. Shapiro, J. Kolesar, G. Otterson, 2009, Cancer Chemotherapy and Pharmacology.

Mitomycin as a modulator of irinotecan anticancer activity.

J. Kolesar, M. Villalona-Calero, 2002, Oncology.

Low-Fat Abiraterone Food Effect Is of Little Consequence.

J. Kolesar, Glenn Liu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palifermin (Kepivance™) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support

J. Kolesar, M. Radtke, 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Gynecologic large cell neuroendocrine carcinoma: A review

J. Kolesar, B. Evers, S. Arnold, 2020, Rare tumors.

Azacitidine: a novel agent for myelodysplastic syndromes.

J. Kolesar, M. Sullivan, Kristine Hahn, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

J. Kolesar, Giangthy N. Ton, Megan Banaszynski, 2013, American Journal of Health-System Pharmacy.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

G. Wilding, J. Kolesar, KyungMann Kim, 2013, Cancer Chemotherapy and Pharmacology.

Stability of unused reconstituted bortezomib in original manufacturer vials

J. Kolesar, L. Vermeulen, M. Pomplun, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.

Ho-Chul Shin, J. Kolesar, G. Kwon, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase

J. Kolesar, H. Robins, Kamakshi Sachidanandam, 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Unexpected doxorubicin-induced cardiomyopathy in sisters

J. Kolesar, H. Robins, Kamakshi Sachidanandam, 2012, International Cancer Conference Journal.

Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.

J. Kolesar, Jason J Bergsbaken, M. Fermiano, 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes

J. Kolesar, L. Vermeulen, Joseph J Bonkowski, 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.

J. Kolesar, Jeff A Engle, 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue.

H. McLeod, K. Kerr, J. Kolesar, 2002, International journal of oncology.

Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine

J. Kolesar, J. Kuhn, A. Morris, 1996 .

Pediatric patient with peritoneal mesothelioma harboring ALK rearrangement

J. Kolesar, Shadi A Qasem, S. Arnold, 2021 .

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer

M. Burkard, J. Kolesar, KyungMann Kim, 2017, Investigational New Drugs.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

J. Kolesar, Jon J Hiles, Jon Hiles, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.

J. Kolesar, A. Tevaarwerk, Amye J. Tevaarwerk, 2009, Clinical therapeutics.

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

G. Wilding, J. Kolesar, R. Brundage, 2011, Cancer Chemotherapy and Pharmacology.

Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags.

J. Kolesar, L. Vermeulen, H. Ikesue, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Ho-Chul Shin, Jill M Kolesar, Ho-Chul Shin, 2011, Molecular pharmaceutics.

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.

G. Wilding, J. Kolesar, J. Eickhoff, 2011, Experimental and therapeutic medicine.

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.

G. Wilding, J. Kolesar, W. Antholine, 2008, Journal of inorganic biochemistry.

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.

J. Kolesar, Shannon a. Kavanaugh, LiSa a. White, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.

J. Kolesar, Jon J Hiles, Kyle N Utecht, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

C. Yiannoutsos, G. Wilding, J. Kolesar, 2005, Clinical Cancer Research.

KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer

Sally R. Ellingson, J. Kolesar, R. Plattner, 2021, Cancers.

Purine nucleoside analogues: fludarabine, pentostatin, and cladribine

J. Kolesar, J. Kuhn, A. Morris, 1996 .

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

R. Gascoyne, S. Horning, J. Kolesar, 2013, Journal of Hematology & Oncology.

Quantitation of Viral Load

J. Kolesar, 2001 .

Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine

J. Kolesar, J. Kuhn, A. Morris, 1997 .

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

J. Huse, J. Kolesar, D. Lyden, 2017, PloS one.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

M. Burkard, J. Kolesar, J. Eickhoff, 2016, Clinical Cancer Research.

Title: Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer Running title: Phase 1 of MK-2206 and lapatinib in combination Authors: 1)

M. Burkard, J. Kolesar, J. Eickhoff, 2016 .

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden

O. Hampton, J. Kolesar, Chi Wang, 2020, PloS one.

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.

J. Kolesar, Zin W. Myint, K. Roubal, 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Stability of a heparin-free 50% ethanol lock solution for central venous catheters

J. Kolesar, J. Johnson, S. Johnston, 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Direct quantification of HIV-1 RNA by capillary electrophoresis with laser-induced fluorescence.

P. G. Allen, J. Kolesar, C. Doran, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Capillary Electrophoresis for Quantitative Genetic Analysis

J. Kolesar, J. Kuhn, 1998 .

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer

J. Kolesar, F. Ueland, J. Gorski, 2020, Diagnostics.

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

J. Siegfried, S. Dacic, J. Kolesar, 2009, Lung cancer.

EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC

J. Kolesar, Kimberly J Gorden, Parvin Mesbah, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)

W. Bshara, K. Kelly, D. Gandara, 2018, Journal of the National Cancer Institute.

Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer

J. Kolesar, M. Palmer, J. Geurink, 2004 .

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

H. McLeod, J. Kolesar, S. Marsh, 2011, Oncology reports.

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

J. Kolesar, Katie A Croegaert, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

T. Greten, G. Wilding, J. Kolesar, 2016, Investigational New Drugs.

EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer

P. Stephenson, J. Kolesar, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology

J. Kolesar, Mahadev Rao, R. Vidya, 2019, Journal of clinical medicine.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

J. Kolesar, Megan Banaszynski, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.

G. Bubley, G. Wilding, J. Kolesar, 2013, Urologic oncology.

Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors

J. Kolesar, Donglin Yan, Zin W. Myint, 2020, JAMA network open.

Lenalidomide-induced elevated bilirubin

J. Kolesar, K. Simondsen, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Pharmacogenetics and irinotecan therapy.

James J. Wolff, J. Kolesar, Kristine Hahn, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Cancer Chemotherapy and Pharmacology.

Prevention and treatment of chemotherapy-induced peripheral neuropathy.

Jill M Kolesar, J. Kolesar, Jennifer Piccolo, 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer

J. Kolesar, H. Gallion, Megan L Hutchcraft, 2021, Diagnostics.

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

R. Jeraj, M. Harrison, G. Wilding, 2011, Clinical Cancer Research.

Targeted therapy for NSCLC: ALK inhibition

J. Kolesar, Rachel Pearson, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

E. Messing, H. Parnes, J. Kolesar, 2012, Cancer Prevention Research.

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

C. Paweletz, P. Jänne, G. Shapiro, 2020, Clinical Cancer Research.

Chemoprevention of breast cancer.

J. Kolesar, A. Thomsen, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

COVID-19 Test Strategy to Guide Quarantine Interval in University Students

F. Romanelli, R. DiPaola, D. Arnett, 2020, medRxiv.

Identification of a Gemcitabine‐Warfarin Interaction

J. Kolesar, Shilpa A. Kinikar, Shilpa A. Kinikar, 1999, Pharmacotherapy.

MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations

Eugene W. Hinderer, Li Chen, Chi Wang, 2020, Bioinform..

Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.

Ruth Warren, Mark E. Burkard, Joshua M. Lang, 2017, JCO precision oncology.

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.

J. Kolesar, Kyle N Utecht, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function.

C. Takimoto, J. Kolesar, J. Wright, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky

J. Kolesar, Bin Huang, S. Arnold, 2020, PloS one.

Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A 549 cells

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2022 .

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Jens Eickhoff, Andreas Friedl, D. McNeel, 2005, Clinical Cancer Research.

Clinical significance of ABCB1 genotyping in oncology

J. Kolesar, Kristine Hahn, Alma Hamidovic, 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Crizotinib for the treatment of non-small-cell lung cancer.

J. Kolesar, A. Timm, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

L. Gordon, J. Kolesar, A. Evens, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy

J. Kolesar, Mahadev Rao, G. Shenoy, 2020, Cancers.

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients

M. Mehta, J. Kolesar, A. Berg, 2011, Anti-cancer drugs.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

J. Kolesar, T. Dennie, 2009, Clinical therapeutics.

Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

G. Wilding, J. Kolesar, J. Schiller, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hydroxyurea induced acute elevations in liver function tests

J. Kolesar, M. Hallam, 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?

J. Kolesar, J. Eickhoff, L. Vermeulen, 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.

J. Kolesar, Jill Kolesar, Marklie Munroe, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

J. Kolesar, D. Mahadevan, C. Deng, 2017, British journal of haematology.

Gastric juice neopterin in Helicobacter pylori infection.

B. Melichar, J. Kolesar, S. Rejchrt, 1995, FEMS immunology and medical microbiology.

Clinical Studies Genotypes of NK Cell KIR Receptors , Their Ligands , and Fc g Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy

J. Maris, J. Kolesar, KyungMann Kim, 2010 .

Genotypes of NK cell KIR Receptors , Their Ligands , and Fc γ Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy : A Children ’ s Oncology Group Report #

J. Kolesar, R. Reisfeld, S. Seo, 2010 .

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel

R. Jeraj, J. Kolesar, C. Liang, 2018, Cancer Chemotherapy and Pharmacology.

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

R. Jeraj, J. Kolesar, S. Perlman, 2011, Cancer Chemotherapy and Pharmacology.

Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2010, Molecular Medicine Reports.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

J. Huse, J. Kolesar, D. Lyden, 2017, Pediatric blood & cancer.

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

G. Wilding, J. Kolesar, K. Tutsch, 2004, Clinical Cancer Research.

Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells.

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2010, Experimental and therapeutic medicine.

Precision medicine: Opportunities for health-system pharmacists

J. Kolesar, L. Vermeulen, 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen

R. Jeraj, J. Kolesar, S. Perlman, 2016, Cancer Chemotherapy and Pharmacology.

Red and white blood cell counts of patients with chronic bronchitis following climatic treatment at 1,330 m altitude

J. Kolesar, V. Slávka, 1965 .

Liquid biopsy approaches for pleural effusion in lung cancer patients

J. Kolesar, Mahadev Rao, R. Damerla, 2020, Molecular Biology Reports.

Vismodegib for the treatment of basal cell skin cancer.

J. Kolesar, L. Poggi, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of vorinostat in combination with bortezomib in refractory solid tumors.

G. Wilding, J. Kolesar, J. Wright, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of vorinostat (NSC 701852 ) in patients (pts) with relapsed non-small cell lung cancer (NSCLC)

J. Kolesar, J. Schiller, J. Eickhoff, 2007 .

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

J. Kolesar, J. R. McCorkle, F. Ueland, 2020, Diagnostics.

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy

E. Messing, H. Parnes, J. Kolesar, 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

J. Kolesar, A. Razak, L. Siu, 2015, Investigational New Drugs.

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

N. Agarwal, B. Costello, R. DiPaola, 2019, Journal of Clinical Oncology.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

J. Kolesar, C. Gaston, 2008, Clinical advances in hematology & oncology : H&O.

Clinical Significance of CYP 2 D 6 Polymorphisms and Tamoxifen in Women with Breast Cancer

J. Kolesar, C. Gaston, 2008 .

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

H. Parnes, J. Kolesar, KyungMann Kim, 2016, American journal of clinical and experimental urology.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

J. Kolesar, A. Argiris, J. Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

Ashley L. Buchanan, J. Kolesar, A. Argiris, 2009, Cancer.

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status

J. Kolesar, S. Arnold, L. Anthony, 2018, Oncotarget.

Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).

S. Ramalingam, J. Kolesar, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

G. Wilding, J. Kolesar, W. See, 2013, The Prostate.

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story

T. Hensing, J. Kolesar, A. Argiris, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Precision medicine in oncology: New practice models and roles for oncology pharmacists.

J. Kolesar, C. Walko, P. Kiel, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Stability of infliximab in polyvinyl chloride bags.

J. Kolesar, Zhisheng Jiang, S. Saha, 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

C. Kyriakopoulos, J. Kolesar, J. Eickhoff, 2017, Investigational New Drugs.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

M. Burkard, J. Kolesar, KyungMann Kim, 2014 .

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

J. Kolesar, J. Schiller, J. Brahmer, 2014, European journal of cancer.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

Pharmacokinetic and Pharmacodynamic Correlative Study of theAntisense Bcl-2 Oligonucleotide G 3139 , in Combinationwith Carboplatin and Paclitaxel , in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008 .

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

G. Wilding, J. Kolesar, J. Eickhoff, 2008, Cancer Chemotherapy and Pharmacology.

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry

J. Kolesar, S. Arnold, A. Mathew, 2021, Cancer medicine.

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

J. Kolesar, Katie L Kabe, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

N. Hanna, F. Hirsch, S. Ramalingam, 2012, Cancer.

New options and controversies in the management of chemotherapy‐induced nausea and vomiting

J. Kolesar, S. Koth, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2011, International Journal of Oncology.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Jill M Kolesar, J. Kolesar, Jeffery S Lafferty, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC)

J. Siegfried, J. Kolesar, J. Schiller, 2005 .

Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer.

J. Kolesar, L. Wilhelm, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Stability of stock and diluted rituximab.

Yang Zhang, J. Kolesar, L. Vermeulen, 2013, American Journal of Health-System Pharmacy.

Assays for biological agents.

J. Kolesar, L. Vermeulen, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky.

J. Villano, J. Kolesar, T. Bocklage, 2020, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.

J. Kolesar, Zhisheng Jiang, R. Ikeda, 2010, Molecular medicine reports.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center

G. Wilding, J. Kolesar, K. Wisinski, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

G. Wilding, J. Kolesar, J. Eickhoff, 2014, Investigational New Drugs.

Novel approaches to anemia associated with cancer and chemotherapy.

J. Kolesar, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Journal of Clinical Oncology.

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

J. Kolesar, Katie A Croegaert, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Ho-Chul Shin, J. Kolesar, G. Kwon, 2011, Molecular pharmaceutics.

Response to Letter of Correspondence – Bastiaens et al.

Albert-László Barabási, Baruch Barzel, Baruch Barzel, 2015, Nature Biotechnology.

Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment

J. Kolesar, Yilin Zhang, J. R. McCorkle, 2021, Diagnostics.

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

J. Kolesar, M. Jones, T. Campbell, 2011, Journal of Clinical Oncology.

Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.

J. Kolesar, Jeff A Engle, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

M. Hidalgo, D. Carbone, J. Kolesar, 2006 .

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer

C. Kyriakopoulos, E. Heath, G. Wilding, 2016, Investigational New Drugs.

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

C. Shapiro, J. Kolesar, M. Villalona-Calero, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

J. Kolesar, L. Vermeulen, E. Mancl, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

J. Kolesar, Jon Hiles, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib

R. Jeraj, G. Wilding, J. Kolesar, 2008 .

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

Ashley L. Buchanan, J. Kolesar, A. Argiris, 2009, Cancer.

Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center – An assessment of occupational infection risk

R. DiPaola, J. Kolesar, C. D. Jennings, 2021, American Journal of Infection Control.

Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas

J. Kolesar, T. Bekaii-Saab, W. Duan, 2005 .

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.